Imexpharm Corporation (HOSE:IMP)

Market Cap	7.47T
Revenue (ttm)	2.21T
Net Income (ttm)	297.54B
Shares Out	154.01M
EPS (ttm)	1,931.94
PE Ratio	25.10
Forward PE	20.05
Dividend	454.55 (0.94%)
Ex-Dividend Date	Jul 11, 2024

Volume	213,700
Average Volume	229,210
Open	47,850
Previous Close	48,000
Day's Range	47,600 - 49,300
52-Week Range	29,136 - 56,500
Beta	0.94
RSI	58.88
Earnings Date	Apr 18, 2025

About Imexpharm

Imexpharm Corporation manufactures, processes, trades, imports, and exports pharmaceutical products in Vietnam and internationally. The company’s products include oral and injectable antibiotic, digestion, central nervous system, cardiovascular, diabetes, ophthalmology, musculoskeletal system, respiratory system, analgesic-anti-inflammatory- antipyretics, anti-histamines, anti-allergy, anti-parasitic, and external drugs, as well as vitamins and minerals, and supplement. It is also involved in the import and export of medical equipment and suppl...

• Industry: Pharmaceutical Preparations
• Founded: 1977
• Employees: 1,452
• Stock Exchange: Ho Chi Minh Stock Exchange
• Ticker Symbol: IMP

Financial Performance

In 2024, Imexpharm's revenue was 2.21 trillion, an increase of 10.59% compared to the previous year's 1.99 trillion. Earnings were 297.54 billion, an increase of 16.85%.